Company news
Milestone Pharmaceuticals Inc. news in 2025
Milestone Pharmaceuticals Inc.'s news releases, calls and decks from 2025, newest first.
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
December 12, 2025
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
November 12, 2025
Milestone Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
November 5, 2025
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
November 3, 2025
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
October 9, 2025
Milestone® Pharmaceuticals to Present at Upcoming Conferences
August 19, 2025
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
August 12, 2025
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
July 11, 2025
Milestone Pharmaceuticals Announces Proposed Public Offering
July 11, 2025
Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
July 11, 2025
Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
June 16, 2025
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 28, 2025
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
May 14, 2025
FDA Issues Complete Response Letter for Etripamil for PSVT
March 28, 2025
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
March 20, 2025
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
March 13, 2025
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
February 27, 2025
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
February 19, 2025
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
January 27, 2025
Decks in 2025
- Corporate Update (December 2025)
Corporate update · 28 slides · Dec 15, 2025
- Investor Day (February 2025)
Investor day · 42 slides · Feb 25, 2025